Observational studyMedicine2025
Clinical analysis of atrial fibrillation after levosimendan treatment for acute decompensated heart failure: A propensity score-matched study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of levosimendan in acute heart failure patients with different body mass index: a multicenter, retrospective, observational real-world study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levosimendan has demonstrated beneficial effects in the treatment of acute decompensated heart failure (ADHF). However, it is also associated with proarrhythmic effects owing to its influence on cardiac electrophysiology. We aimed to analyze the clinical features of atrial fibrillation (AF) after levosimendan treatment in patients with ADHF and to identify the predictors of AF after levosimendan treatment. The data of patients with ADHF treated with levosimendan were propensity score-matched and retrospectively analyzed. This study retrospectively collected patients admitted to the emergency department between 2021 and 2024 with a diagnosis of acute decompensated heart failure who received levosimendan therapy. Overall, 38 patients (16.8%) developed AF after levosimendan treatment. Levosimendan therapy was an independent predictor of AF (odds ratio 1.442, 95% confidence interval 1.005-2.067; P = .014). Patients who developed AF were older (P < .001) and more likely to have comorbid left atrial enlargement (P < .001) and previous AF/atrial flutter (P = .004). Patients with AF after levosimendan treatment had a longer median in-hospital stay than those without AF. Age (P = .005), left atrial enlargement (P = .032), and history of atrial flutter/AF (P = .002) were significant predictors of AF after levosimendan treatment. The area under the receiver operating characteristic curve values for age, left atrial enlargement, and history of atrial flutter/AF for predicting AF after treatment with levosimendan were 0.679 (P < .001), 0.687 (P < .001), and 0.603 (P = .012), respectively. Age, left atrial enlargement, and previous atrial flutter/AF were independent predictors of AF after levosimendan treatment. Levosimendan-associated AF increased the length of in-hospital stay, but had no effect on in-hospital mortality. Although this was a retrospective study, the study was registered as a clinical study, and the registration numbers will be uploaded later.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.